Sucharita Mistry, PhD

The remote monitoring intervention reduced the rate of grade 3 or higher adverse events and the length of hospital stays.

Immunotherapy prolonged survival compared with platinum chemotherapy.

Having a high blood tumor mutational burden was associated with a significant improvement in response and a trend toward improvement in survival outcomes.

Segmentectomy prolonged 5-year overall survival in a phase 3 trial.

Adding nivolumab to chemotherapy improved the pathologic complete response rate and prolonged event-free survival.

The cumulative incidence of intracranial hemorrhage at 1 year was 22.5% in patients who received antiplatelet agents and 19.3% in those who did not.

Adding ipilimumab to pembrolizumab did not improve survival outcomes.

Overall survival was significantly longer for patients who received sintilimab plus chemotherapy than for those who received placebo plus chemotherapy.

Furmonertinib improved progression-free survival and appeared safer than gefitinib in a phase 3 trial.

Camrelizumab improved overall survival, even when adjusting for crossover.

Adding toripalimab to chemotherapy led to a 31% reduction in the risk of death for patients with advanced NSCLC.

Researchers examined whether ES-IMRT provides a meaningful reduction in esophageal symptoms compared with standard radiotherapy.

The median progression-free survival was 20.2 months in the radiotherapy arm and 12.5 months in patients who received a tyrosine kinase inhibitor alone.

Managing symptoms based on patient-reported outcomes may reduce symptom burden and complications after lung cancer surgery.

The approach improved risk assessment compared with 2021 USPSTF screening criteria.

The high frequency of pneumonitis “is a serious concern,” according to researchers.

ctDNA positivity was associated with worse recurrence-free survival.

The 1-year overall survival rate was 59% with chemotherapy plus immunotherapy and 55% with immunotherapy alone.

Five studies showed a negative association between quality of life and unmet needs.

STK11 and KEAP1 mutations were independent predictors of shorter progression-free and overall survival in KRAS-mutant cases.

Proton pump inhibitor use was tied to worse overall and progression-free survival.

Gefitinib did not improve disease-free or overall survival.

The median progression-free survival was 3.0 months in the nivolumab arm and 1.8 months in the placebo arm.

Most patients studied did not have thyroid labs obtained after immune checkpoint inhibitor treatment.

The confirmed response rate was 27%, and the median progression-free survival was 5.5 months.

The technology could save patients from ineffective treatment, according to researchers.

Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

Response and survival outcomes differed according to the tumor microenvironment.

The highest response rate observed with any therapy was 25%.